You are here

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Correspondence on ‘A pilot study of tofacitinib for refractory Behçet’s syndrome’’ by Zou et al
  1. Jinjing Liu1,
  2. Chan Zhao2,
  3. Wenjie Zheng1
  1. 1 Department of Rheumatology and Clinical Immunology, Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
  2. 2 Department of Ophthalmology, Peking Union Medical College Hospital, Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
  1. Correspondence to Professor Wenjie Zheng, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing 100730, China; wenjzheng{at}gmail.com

http://dx.doi.org/10.1136/annrheumdis-2020-219828

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Zou and colleagues for their interests and insightful comments1 on our recently published work2 and are impressed by the encouraging results of tofacitinib on patients with refractory Behçet’s uveitis (BU).

    In this study, 5 mg two times per day tofacitinib was given to active patients with BU with prednisone reduced from 50 to 60 mg per day to 30 mg per day and withdrawal of conventional immunosuppressants (cyclosporine A or tacrolimus), which lead to treatment ‘success’ and ‘flare’ in 10 (76.9%) and 3 (23.1%) of the 13 included patients, respectively. Moreover, all the 10 patients responded to …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors All authors equally contributed to the writing of the manuscript. CZ and WZ are the corresponding authors.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles